Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1
Related Experiment Video
Updated: Aug 19, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Jerome Guillemont1, Elisabeth Pasquier, Patrice Palandjian
1Medicinal Chemistry Department, Johnson & Johnson Pharmaceutical Research and Development, Campus de Maigremont BP615, Val de Reuil, France. jguillem@prdfr.jnj.com
Abstract:
This paper reports the synthesis and the antiviral properties of new diarylpyrimidine (DAPY) compounds as nonnucleoside reverse transcriptase inhibitors (NNRTIs). The synthesis program around this new DAPY series was further optimized to produce compounds displaying improved activity against a panel of eight clinically relevant single and double mutant strains of human immunodeficiency virus type 1 (HIV-1).
Related Concept Videos
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
DNA Base Pairing
Retrovirus Life Cycles
Inhibitors Of Virion Release
